Established science, novel combination -- our early-stage research is designed to test each critical piece, and then whether they function together as one platform. Here's what that program is actually asking.
We are testing whether the Atraxis™ delivery platform can reliably present NeoTag™ signals where they need to be, across both development tracks.
Once a signal is installed, we are testing whether it actually draws immune attention.
Only reached if question one succeedsThese are research questions we are testing, not outcomes we are predicting. Every description on this page reflects a design objective grounded in published biology, not a demonstrated result. Detailed study design and success criteria go to prospective investors as part of diligence rather than being published here.
MSS colorectal cancer and pancreatic cancer are both large patient populations where current immunotherapy offers limited benefit, and both are immune-cold for reasons a recognition-focused platform is designed to address.
Running both tracks from one program tests the recognition thesis in two independent settings rather than one.
The epidemiology behind both choicesSpecific timelines and vendor detail are deliberately kept off this page; those live in the investor package. This is the general shape of the path we are on.
Where we are now: testing installation and recognition, the two questions above.
Expanding from an initial signal to broader validation across both indications.
Cytotoxicity and broader efficacy questions, once recognition is established.
The studies required to support a future clinical filing.
Sequence, not a schedule. Each stage begins only if the one before it succeeds, so no dates are implied by the order.
Meet the team and the scientific advisory board behind the program.